DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure
15 juil. 2019 09h00 HE
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, July 15, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced the start of a phase 2 randomized, double-blind, placebo-controlled trial to evaluate...
Cohera Medical Inc.® Awarded Patent on its Biodegradable Sealant Technology
25 avr. 2018 07h00 HE
|
Cohera Medical, Inc.
RALEIGH, N.C., April 25, 2018 (GLOBE NEWSWIRE) -- Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that the U.S. Patent and...
ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China
18 janv. 2018 01h00 HE
|
ASLAN Pharmaceuticals
SINGAPORE , Jan. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Announces Shortened Timeline to Commercialisation for Varlitinib in China
08 janv. 2018 01h00 HE
|
ASLAN Pharmaceuticals
SINGAPORE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
04 janv. 2018 02h00 HE
|
ASLAN Pharmaceuticals
SINGAPORE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for Varlitinib From Array BioPharma
03 janv. 2018 03h00 HE
|
ASLAN Pharmaceuticals
SINGAPORE, Jan. 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
Colon Cancer Alliance and Allsup Help Former Workers Avoid Disability Backlog
15 août 2017 10h51 HE
|
Allsup
Belleville, Illinois, Aug. 15, 2017 (GLOBE NEWSWIRE) -- The Colon Cancer Alliance and Allsup, a national provider of Social Security Disability Insurance (SSDI) representation, today announced a...
Carcinoembryonic Antigen Market to hit $2.7bn by 2023: Global Market Insights, Inc.
20 avr. 2017 06h30 HE
|
Global Market Insights, Inc
Ocean View, Delaware, April 20, 2017 (GLOBE NEWSWIRE) -- The research report “Carcinoembryonic Antigen (CEA) Market Size By Application (Colorectal, Pancreatic, Ovarian, Breast, Thyroid Cancer),...
Cohera Medical, Inc.® Receives FDA Approval to Begin Clinical Trials of its Sylys® Surgical Sealant in the U.S.
12 juil. 2016 09h30 HE
|
Cohera Medical, Inc.
RALEIGH, N.C., July 12, 2016 (GLOBE NEWSWIRE) -- Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that it has received...
Carcinoembryonic antigen (CEA) market size worth $2.78 Billion by 2023: Global Market Insights Inc.
16 mai 2016 07h30 HE
|
Global Market Insights, Inc
Dover, DE, May 16, 2016 (GLOBE NEWSWIRE) -- Carcinoembryonic antigen (CEA) market size is forecast to reach USD 2.78 billion by 2023; as reported in the latest study by Global Market Insights,...